DOK7 Gene Therapy Enhances Neuromuscular Junction Innervation and Motor Function in Aged Mice

被引:24
|
作者
Ueta, Ryo [1 ]
Sugita, Satoshi [2 ]
Minegishi, Yoshihiko [2 ]
Shimotoyodome, Akira [2 ]
Ota, Noriyasu [2 ]
Ogiso, Noboru [3 ]
Eguchi, Takahiro [1 ]
Yamanashi, Yuji [1 ]
机构
[1] Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Genet,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan
[2] Kao Corp, Biol Sci Res, 2606 Akabane, Ichikai, Tochigi 3213497, Japan
[3] Natl Ctr Geriatr & Gerontol, Lab Expt Anim, 7-430 Morioka Cho, Obu, Aichi 4748511, Japan
关键词
ADENOASSOCIATED VIRUS VECTOR; HUMAN SKELETAL-MUSCLE; CROSS-SECTIONAL AREA; ACETYLCHOLINE-RECEPTOR; LRP4; FIBERS; FORCE; DYSFUNCTION; EXERCISE; DEFECTS;
D O I
10.1016/j.isci.2020.101385
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Muscle denervation at the neuromuscular junction (NMJ), the essential synapse between motor neuron and skeletal muscle, is associated with age-related motor impairment. Therefore, improving muscle innervation at aged NMJs may be an effective therapeutic strategy for treating the impairment. We previously demonstrated that the muscle protein Dok-7 plays an essential role in NMJ forma-tion, and, indeed, its forced expression in muscle enlarges NMJs. Moreover, therapeutic administration of an adeno-associated virus vector encoding human Dok-7 (DOK7 gene therapy) suppressed muscle denervation and enhanced motor activity in a mouse model of amyotrophic lateral sclerosis (ALS). Here, we show that DOK7 gene therapy significantly enhances motor function and muscle strength together with NMJ innervation in aged mice. Furthermore, the treated mice showed greatly increased compound muscle action potential (CMAP) ampli-tudes compared with the controls, suggesting enhanced neuromuscular transmis-sion. Thus, therapies aimed at enhancing NMJ innervation have potential for treating age-related motor impairment.
引用
收藏
页数:18
相关论文
共 24 条
  • [21] Subpial delivery of adeno-associated virus 9-synapsin- caveolin-1 (AAV9-SynCavl) preserves motor neuron and neuromuscular junction morphology, motor function, delays disease onset, and extends survival in hSOD1G93A mice
    Wang, Shanshan
    Ichinomiya, Taiga
    Savchenko, Paul
    Wang, Dongsheng
    Sawada, Atsushi
    Li, Xiaojing
    Duong, Tiffany
    Li, Wenxi
    Bonds, Jacqueline A.
    Kim, Eun Jung
    Miyanohara, Atsushi
    Roth, Dave M.
    Patel, Hemal H.
    Patel, Piyush M.
    Tadokoro, Takahiro
    Marsala, Martin
    Head, Brian P.
    THERANOSTICS, 2022, 12 (12): : 5389 - 5403
  • [22] Low-Dose Intracerebroventricular Delivery of a Second-Generation AAV Gene Therapy for Spinal Muscular Atrophy Achieves Efficient and Toxicity-Free Motor Function Rescue in Mice
    Chen, Xiupeng
    Xie, Qing
    Ma, Hong
    Ma, Yijie
    Jalinous, Leila
    Yang, Jun
    Zhu, Yunxiang
    Su, Qin
    Tai, Phillip W. L.
    Gao, Guangping
    Xie, Jun
    MOLECULAR THERAPY, 2023, 31 (04) : 348 - 348
  • [23] AAV2/8-MEDIATED GENE THERAPY PROVIDES PROLONGED PROTECTION AGAINST BIOCHEMICAL INDUCTION OF ACUTE ATTACKS AND IMPROVES MOTOR FUNCTION IN ACUTE INTERMITTENT PORPHYRIA MICE
    Yasuda, M.
    Bishop, D. F.
    Fowkes, M. E.
    Cheng, S. H.
    Gan, L.
    Desnick, R. J.
    MOLECULAR GENETICS AND METABOLISM, 2009, 98 (1-2) : 139 - 139
  • [24] AAV1.NT-3 Gene Therapy Attenuates Age-Related Musculoskeletal Changes and Improves Function in the Wild Type-Aged C57BL/6J Mice
    Ozes, Burcak
    Myers, Morgan
    Moss, Kyle
    Ridgley, Alicia
    Chen, Lei
    Murrey, Darren
    Sahenk, Zarife
    MOLECULAR THERAPY, 2020, 28 (04) : 489 - 490